Faculty/Authors
Meghan E. Kapp, MD Morvarid Elahi, MD Sara Akhavanfard, MD, PhD Jessica Sigel, MD University Hospitals Cleveland Medical Center Case Western Reserve University Cleveland, Ohio
CME or CMLE Credit: 2.0
Estimated Completion Time: 2 hoursFormat: Online Educational Activity and Post Exam Physician Competencies: Patient Care, Medical KnowledgeEligibility for CME/CMLE credit: Max three attempts. You will have a maximum of three attempts to meet the following criteria:
Default Credit Type: None (You must meet the eligibility requirements in order to obtain CME credit.) Accreditation Statement: The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians. This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME).Credit Designation Statement: The American Society for Clinical Pathology (ASCP) designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions
To claim CME credit for the exercise, do the following:
To claim CMLE credit for the exercise, do the following:
Faculty Disclosures
Technical ConsiderationsRelease Date: 12/31/2025 Review Date:Expiration Date: 12/31/2027
describe the pathophysiology of Fabry disease, including the role of α-galactosidase A deficiency and globotriaosyceramide (GB3);
identify key diagnostic approaches for Fabry disease, including enzymatic activity assays and genetic testing of the GLA gene;
explain the natural history and pathologic findings of Fabry nephropathy, including early podocyte injury, proteinuria, and characteristic histologic/electron microscopic features (myeloid bodies);
compare and evaluate therapeutic options for Fabry disease, including enyzme replacement therapy (ERT) and chaperone therapy (e.g. migalastat); and
apply case-based knowledge to identify Fabry disease in patients with unexplained chronic kidney disease or hypertrophic cardiomyopathy to avoid diagnostic delays.